Evidence map›Paper›PMID 32193642›Full record

ReviewEuropean radiology2020

Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know.

Marco Calandri, Giulia Siravegna, Steven M Yevich, Giuseppe Stranieri, Carlo Gazzera, Scott Kopetz, Paolo Fonio, Sanjay Gupta, Alberto Bardelli, Andrea Veltri and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Marco Calandri *Radiology Unit, A.O.U. San Luigi Gonzaga - Orbassano (To), Orbassano, TO, Italy.
Giulia Siravegna *Candiolo Cancer Institute-FPO, IRCCS, Candiolo (To), Candiolo, TO, Italy.
Steven M YevichDepartment of Interventional Radiology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Giuseppe StranieriRadiology Unit, A.O.U. San Luigi Gonzaga - Orbassano (To), Orbassano, TO, Italy.
Carlo GazzeraRadiology Institute, Città della Salute e della Scienza - Torino Department of Surgical Sciences, University of Turin, Turin, Italy.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Paolo FonioRadiology Institute, Città della Salute e della Scienza - Torino Department of Surgical Sciences, University of Turin, Turin, Italy.
Sanjay GuptaDepartment of Interventional Radiology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Alberto BardelliDepartment of Oncology, University of Torino, Turin, Italy.
Andrea Veltri *Radiology Unit, A.O.U. San Luigi Gonzaga - Orbassano (To), Orbassano, TO, Italy.
Bruno C Odisio *Department of Interventional Radiology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA. BCOdisio@mdanderson.org.ORCID http://orcid.org/0000-0002-1771-8233
The University of Texas MD Anderson Cancer Center · USOspedale San Luigi Gonzaga · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCandiolo Cancer Institute · ITHarvard University · US

Funding

Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
A.I.R.C. IG 2018 ID. 21091; IG 2015 n. 16788; AIRC IG 2018 - ID. 21923 projectNCATS NIH HHS KL2 TR000370NCI NIH HHS RCA235564ARoche Italia Roche per la ricerca 2017Siemens Healthineers research grant
6 · The paper itself

Abstract

The acquisition of adequate tumor sample is required to verify primary tumor type and specific biomarkers and to assess response to therapy. Historically, invasive surgical procedures were the standard methods to acquire tumor samples until advancements in imaging and minimally invasive equipment facilitated the paradigm shift image-guided biopsy. Image-guided biopsy has improved sampling yield and minimized risk to the patient; however, there are still limitations, such as its invasive nature and its consequent limitations to longitudinal tumor monitoring. The next paradigm shift in sampling technique will need to address these issues to provide a more reliable and less invasive technique. Recently, liquid biopsy (LB) has emerged as a non-invasive alternative to tissue sampling. This technique relies on direct sampling of blood or other bodily fluids in contact with the tumor in order to collect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating RNAs-in particular microRNA (miRNAs). Clinical applications of LB involve different steps of cancer patient management including screening, detection of disease recurrence, and evaluation of acquired resistance. With any paradigm shift, old techniques are often relegated to a secondary option. Although image-guided biopsies may appear as a passive spectator on the rapid advancement of LB, the two techniques may well be codependent. Interventional radiology may be integral to directly sample the liquid surrounding or draining from the tumor. In addition, LB may help to correctly select the patients for image-guided loco-regional treatments, to determine its treatment endpoint, and to early detect recurrence. KEY POINTS: • Liquid biopsy is a novel technology with potential high impact in the management of patients undergoing image-guided procedures. • Interventional radiology procedures may increase liquid biopsy sensitivity through direct fluid sampling. • Liquid biopsy techniques may provide a venue for improving patients' selection and enhance outcomes of interventional loco-regional therapies performed by interventional radiologists.

Indexed as

Biomarkers, TumorHumansImage-Guided BiopsyLiquid BiopsyNeoplasmsNeoplastic Cells, CirculatingRadiologistsRadiology, InterventionalBiomarkers, TumorBiomarkerImage-guided biopsyInterventional radiologyLiquid biopsyThermal ablation

Identifiers

PMID32193642
OpenAlexW3011093513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.